diltiazem has been researched along with 2019 Novel Coronavirus Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bu, Z; Cao, H; Ge, J; He, X; Hua, R; Liu, R; Luo, J; Shuai, L; Sun, Z; Wang, C; Wang, J; Wang, X; Wen, Z; Zhong, G | 1 |
| Brun, P; Constant, S; Dubois, J; Dulière, V; Errazuriz-Cerda, E; Fouret, J; Gaymard, A; Julien, T; Lescure, FX; Lina, B; Padey, B; Pizzorno, A; Poissy, J; Rosa-Calatrava, M; Terrier, O; Traversier, A; Trouillet-Assant, S; Yazdanpanah, Y | 1 |
2 other study(ies) available for diltiazem and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung.
Topics: A549 Cells; Animals; Cells, Cultured; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Diltiazem; Disease Models, Animal; Female; HEK293 Cells; HeLa Cells; Humans; Lung; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; SARS-CoV-2; Vero Cells; Virus Attachment; Virus Internalization | 2022 |
Characterization and Treatment of SARS-CoV-2 in Nasal and Bronchial Human Airway Epithelia.
Topics: Adenosine Monophosphate; Airway Remodeling; Alanine; Animals; Antiviral Agents; Bronchi; Chlorocebus aethiops; COVID-19; COVID-19 Drug Treatment; Diltiazem; Drug Synergism; Humans; Immunity, Innate; Models, Biological; Nose; Respiratory Mucosa; SARS-CoV-2; Vero Cells | 2020 |